Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 3/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | GRN | P28799 | 1/20 | 0.32 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL272814 | 0.79 | NR1H2 (0.39) | NR1H2NR1H3ESR1ESR2ALDH1A1 | |
| SCHEMBL152027 | 0.79 | NR1H2 (0.39) | NR1H2NR1H3ESR1ESR2ALDH1A1 | |
| SCHEMBL26197740 | 0.77 | ACHE (0.40) | NR1H2NR1H3ALDH1A1MAPTKMT2A | |
| SCHEMBL272396 | 0.77 | ESR1 (0.43) | NR1H2NR1H3ESR1ESR2ALDH1A1 | |
| Water SCHEMBL3812783 | 0.77 | NR1H2 (0.38) | NR1H2NR1H3ESR1ESR2ALDH1A1 | |
| SCHEMBL26197113 | 0.75 | LMNA (0.48) | NR1H2NR1H3ALDH1A1ALOX15KMT2A | |
| SCHEMBL25381575 | 0.75 | HPGD (0.57) | ALDH1A1ALOX15TSHRCES2CES1 | |
| SCHEMBL29029634 | 0.74 | NR1H2 (0.35) | NR1H2NR1H3ESR1ESR2ALDH1A1 | |
| SCHEMBL29749402 | 0.72 | ESR1 (0.37) | NR1H2NR1H3ESR1ESR2ALDH1A1 | |
| SCHEMBL3526796 | 0.72 | ESR1 (0.37) | NR1H2NR1H3ESR1ESR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673942-B2 | Fused ring compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-18 | — | — | US | claimed |
| US-8993470-B2 | Catalysts for the alkyne metathesis | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2015-03-31 | — | — | US | disclosed |
| EP-2556078-B1 | CATALYSTS FOR ALKYNE METATHESIS | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2014-09-24 | — | — | EP | disclosed |
| US-8673942-B2 | Fused ring compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-18 | — | — | US | disclosed |
| US-8557805-B2 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-15 | — | — | US | disclosed |
| US-20130144102-A1 | CATALYSTS FOR THE ALKYNE METATHESIS | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2013-06-06 | — | — | US | disclosed |
| EP-2556078-A1 | CATALYSTS FOR ALKYNE METATHESIS | Studiengesellschaft Kohle MbH (DE) | 2013-02-13 | — | — | EP | disclosed |
| US-20120035163-A1 | NOVEL FUSED RING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-02-09 | — | — | US | disclosed |
| WO-2011120508-A1 | CATALYSTS FOR ALKYNE METATHESIS | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2011-10-06 | — | — | WO | disclosed |
| EP-2371826-A1 | NOVEL FUSED RING COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-10-05 | — | — | EP | disclosed |
| US-5670489-A | USEFUL IN TREATMENT OF DISEASES WHICH ARE MODULATED BY PROTEINS, OR IN TREATMENT OF VIRUSES SUCH AS INFLUENZA, HERPES, AND HIV | NOVARTIS CORPORATION (US) | 1997-09-23 | — | — | US | disclosed |
| US-5656753-A | 4-substituted azetidinones as precursors to 2-substituted-3-carboxy carbapenem antibiotics and a method of producing them | AMERICAN CYANAMID COMPANY (US) | 1997-08-12 | — | — | US | disclosed |
| US-5508270-A | Nucleoside phosphinate compounds and compositions | CIBA-GEIGY CORPORATION (US) | 1996-04-16 | — | — | US | disclosed |
| US-5466677-A | Dinucleoside phosphinates and their pharmaceutical compositions | CIBA-GEIGY CORPORATION (US) | 1995-11-14 | — | — | US | disclosed |
| US-5371215-A | 4-substituted azetidinones as precursors to 2-substituted-3-carboxy carbapenem antibiotics and a method of producing them | AMERICAN CYANAMID COMPANY (US) | 1994-12-06 | — | — | US | disclosed |
| EP-0614906-A1 | Mononucleotide analogues and intermediates therefor | CIBA-GEIGY AG (CH) | 1994-09-14 | — | — | EP | disclosed |
| EP-0614907-A1 | Dinucleotide and oligonucleotide analogues | CIBA-GEIGY AG (CH) | 1994-09-14 | — | — | EP | disclosed |
| US-5189158-A | 4-SUBSTITUTED AZETIDINONES AS PRECURSORS TO 2-SUBSTITUTED-3-CARBOXY CARBAPENEM ANTIBIOTICS AND A METHOD OF PRODUCING THEM | AMERICAN CYANAMID COMPANY (US) | 1993-02-23 | — | — | US | disclosed |
| EP-0504612-A2 | Novel 4-substituted azetidinones as precursors to 2-substituted-3-carboxy carbapenem antibiotics and a method of producing them | AMERICAN CYANAMID COMPANY (US) | 1992-09-23 | — | — | EP | disclosed |
| US-5100762-A | Radiation-sensitive polymer and radiation-sensitive composition containing the same | MITSUBISHI DENKI KABUSHIKI KAISHA (JP) | 1992-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130144102-A1 | CATALYSTS FOR THE ALKYNE METATHESIS | MSH6, AP3M1, PMS2 | NR1H2 2603/4885NR1H3 2796/4885ESR1 2842/4885 |
| US-20120035163-A1 | NOVEL FUSED RING COMPOUND AND USE THEREOF | GPR119, GCKR, SLC5A1 | NR1H2 1189/4885NR1H3 1204/4885ESR1 2367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.